ArticleLeukemia2020

The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.

Arnon Nagler et al.PubMed ↗Publisher ↗

No numbers read from the abstract.